跳至主要内容
临床试验/ACTRN12621001371886
ACTRN12621001371886已完成未知

Optical Coherence Tomography Angiography Biomarkers that Predict Early Response to Anti-VEGF Therapy in Diabetic Macular Oedema.

ions Eye Institute0 个研究点目标入组 48 人开始时间: 2021年10月11日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Age greater or equal to 18 years
  • Type 1 or 2 diabetes mellitus
  • Diabetic macular oedema (both treatment naive and previously treated) causing vision loss, with study eye BCVA measuring 0.3 to 1.0 logarithm of the minimum angle of resolution; macular oedema defined clinically and by retinal thickness of <250um in the central subfield; and intraretinal or subretinal fluid seen on SD-OCT.

排除标准

  • Another concomitant ocular disease that causes macular oedema such as age-related macular degeneration or retinal vein occlusion.
  • Another ocular condition that compromises visual acuity, except for the presence of cataract.
  • Previous treatment with intraocular corticosteroids within the 6 months of the baseline visit.

研究者

发起方
ions Eye Institute

相似试验

Optical Coherence Tomography Angiography Biomarkers... | 临床试验